Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19983331 | 0.85 | TDP1 (0.44) | FOLH1TDP1ATMCTSLCTSK | |
| SCHEMBL21152481 | 0.84 | FOLH1 (0.50) | FOLH1TDP1ATMCTSLCTSK | |
| SCHEMBL19983324 | 0.84 | FOLH1 (0.50) | FOLH1TDP1ATMCTSLCTSK | |
| SCHEMBL23023495 | 0.82 | TDP1 (0.54) | FOLH1TDP1ATMMAPTKDM4E | |
| SCHEMBL19983018 | 0.82 | TDP1 (0.54) | FOLH1TDP1ATMMAPTKDM4E | |
| SCHEMBL25660426 | 0.80 | CTSK (0.54) | FOLH1TDP1ATMCTSLCTSK | |
| SCHEMBL19983059 | 0.80 | CTSK (0.54) | FOLH1TDP1ATMCTSLCTSK | |
| SCHEMBL19983323 | 0.77 | CTSL (0.72) | FOLH1TDP1ATMCTSLCTSK | |
| SCHEMBL19983337 | 0.77 | CTSL (0.43) | FOLH1TDP1ATMCTSLCTSK | |
| SCHEMBL19983330 | 0.77 | CTSL (0.43) | FOLH1TDP1ATMCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2018053353-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730826-B2 | Ketone inhibitors of lysine gingipain | PHYKPL, ENPEP, PREP | FOLH1 280/4885TDP1 1585/4885ATM 3237/4885 |
| US-20190210960-A1 | KETONE INHIBITORS OF LYSINE GINGIPAIN | PHYKPL, ENPEP, PREP | FOLH1 280/4885TDP1 1585/4885ATM 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.